Compass Pathways PLC

This resolution asks shareholders to grant the Company’s Audit and Risk Committee authority to determine and approve the auditors’ remuneration for the coming fiscal year. Management is seeking this authorization because, under the Company’s governance framework, the Audit and Risk Committee has primary responsibility for appointing, retaining, and assessing the independence of the external auditors and for pre-approving audit and permissible non-audit services; delegating remuneration authority to that committee aligns responsibility and accountability. The proposal is routine in corporate practice but important: it ensures the committee can negotiate and approve fees promptly, without requiring full board action for operational matters, preserving the committee’s independence and oversight role. The proxy statement explains that fees for PwC US and PwC UK for recent years have been pre-approved and that the committee follows written pre-approval procedures; the committee’s authority also allows it to delegate certain pre-approvals to the committee chair consistent with policy. Vote recommendation is FOR; the Board’s rationale emphasizes continuity, independent committee oversight of auditor compensation to preserve auditor independence, and administrative efficiency. From a governance perspective, allowing the audit committee to set fees reduces potential conflicts of interest and aligns with best practices under U.K. and U.S. rules. If shareholders were to vote against this, practical effect would be limited because the committee already has responsibility, but a negative vote could signal shareholder concern about audit arrangements or fees and prompt the committee to engage with investors and disclose further rationale.

This resolution asks shareholders to receive the Company’s U.K. statutory annual accounts and reports for the year ended December 31, 2025 and to note that the directors are not recommending a dividend for the year. Management includes this as a routine presentation under U.K. Companies Act requirements—shareholder receipt of statutory accounts and reports is largely a formal step that provides transparency and an opportunity for shareholder questions. The Company’s proxy states that the 2025 Annual Report (including audited accounts and the statutory directors’ remuneration disclosures) will be made available to shareholders and that the Board will present them at the AGM. The Board recommends a vote FOR because receiving the accounts formalizes shareholder review of audited financials and directors’ commentary and is consistent with the Board’s obligations; the recommendation also reflects the Board’s assessment that no dividend is appropriate given the Company’s stage and capital allocation priorities. From an investor governance viewpoint, this vote is non-binding in influence but signals that the financial statements and disclosures have been made available and invites shareholder scrutiny. A dissenting vote would not change the accounts but could be interpreted as shareholder concern about the Company’s financial disclosures, results, or dividend policy and would likely prompt management and the Board to engage with investors and explain decisions on capital deployment. The resolution enables a public record of shareholders’ reception of the statutory accounts and supports the Company’s compliance with U.K. reporting obligations.

This advisory resolution asks shareholders to approve the Company’s statutory directors’ remuneration report, which details remuneration policy, pay outcomes and the link between pay and performance for the year ended December 31, 2025. Management’s case is that the remuneration report transparently explains how board and executive pay is structured—mixing base salary, annual cash bonuses tied to corporate objectives, and long-term equity incentives (options and RSUs)—and that the Compensation and Leadership Development Committee exercises governance controls, including independent advisor engagement and clawback policies. The vote is non-binding under U.K. and U.S. practice, but the Board states it will carefully consider the outcome when making future remuneration decisions; historically the Company received strong shareholder support for pay practices. The Board recommends FOR, arguing that the report aligns pay with long-term shareholder value, uses market benchmarking (including a defined peer group), and that compensation is predominantly “at-risk” via equity. An adverse vote would be important signaling to the Compensation Committee and could trigger engagement, potential policy adjustments, or enhanced disclosure; it would not automatically change compensation but would increase investor scrutiny. For sophisticated analysts, key issues include the balance of equity vs cash, the committee’s discretion on performance adjustments, change-in-control provisions, and the degree to which incentive metrics are explicit versus qualitative; the report’s descriptions of peer benchmarking, target bonus levels, and long-term incentive grant practices are central to evaluating alignment with shareholder interests.

This advisory 'say-on-pay' proposal asks shareholders to endorse the Company’s disclosed executive compensation for the named executive officers for 2025, including base salaries, target and actual cash bonuses, and long-term equity awards (mix of options and RSUs). Management frames the program as pay-for-performance: target bonuses tied to corporate objectives (NDA readiness, Phase 3 program execution, capitalization and commercial preparedness) and a heavy equity-based long-term component to align executives with shareholder value creation. The Compensation and Leadership Development Committee retained independent advisor Aon, used a biotech peer group for benchmarking, and structured awards (mix and vesting) to promote retention and long-term alignment; the proxy discloses target bonus percentages, actual payouts, and equity grant practices. The vote is non-binding, but the Board says it will review results and consider investor feedback; the Company previously received high say-on-pay support in 2025, which the committee cites as evidence of shareholder alignment. The Board recommends FOR, noting that compensation is designed to be competitive, largely at-risk, and governed by independent committee review and clawback policy—key elements to mitigate excessive risk-taking. For an analyst, important considerations include the transparency and specificity of performance metrics, the balance of time-based RSUs vs market-priced options, severance/change-in-control protections, and whether equity grants and bonus outcomes are calibrated to realized shareholder returns and clinical/regulatory milestones. A substantial negative vote would signal investor concern and likely trigger targeted engagement and potential adjustments to bonus metrics, disclosure, or long-term incentive design.